NOTICE IN RELATION TO WAIVER OF LOCK-UP RESTRICTION
27 Décembre 2017 - 7:00AM
YASTEST
REGULATED INFORMATION
GHENT, Belgium,
27 December 2017 - Ablynx [Euronext Brussels
and Nasdaq: ABLX] today announced that Merrill Lynch, Pierce,
Fenner & Smith Incorporated, J.P. Morgan Securities LLC
and Jefferies LLC, the lead book-running managers in the Company's
recent public sale of 13,144,500 ordinary shares in the form of
American Depositary Shares, including 1,714,500 ordinary shares
from the full exercise of the underwriters' option, are waiving a
lock-up restriction with respect to 18,750 ordinary shares of the
Company held by an officer of the Company. The waiver will take
effect on 29 December 2017 and the securities may be sold on or
after such date. The purpose of the waiver is to allow the officer
to make certain transfers for value to affiliated persons.
This press release is not an offer
for sale of the securities in the United States or in any other
jurisdiction where such offer is prohibited, and such securities
may not be offered or sold in the United States absent registration
or an exemption from registration under the United States
Securities Act of 1933, as amended.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
pdf version of press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Ablynx NV (NASDAQ:ABLX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Ablynx NV (NASDAQ:ABLX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024